Esperion (NASDAQ:ESPR) today announced preliminary, unaudited fourth-quarter 2022 financial results and highlighted key upcoming anticipated milestones which represent continued execution of the Company’s transformational plan.
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals –
– Fourth quarter 2022 U.S. net product revenue estimated between $14.4 to $15.1 million, FY growth between 38% and 40% year over year –
– New partnership with RFK Racing to increase brand awareness and drive accelerated growth –
– Company presenting at J.P. Morgan 41st Annual Healthcare Conference –
